PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.66%
Cash & equivalents declining -8.66% while Medical - Pharmaceuticals shows 1.95% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-8.66%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -1.94%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-19.00%
Receivables growth is below half the Medical - Pharmaceuticals median of 1.42% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
-0.48%
Inventory growth less than half of Medical - Pharmaceuticals median of 3.93%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
50.43%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-2.62%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -0.63%. Joel Greenblatt sees a potential liquidity edge if well allocated.
2.79%
PP&E growth below half of Medical - Pharmaceuticals median of -0.28%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
0.61%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
0.61%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
22.40%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-292.17%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
107.08%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.59%
Below half the Medical - Pharmaceuticals median of -0.31%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
200.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
0.68%
Near the Medical - Pharmaceuticals median of 0.68%. Charlie Munger sees typical asset growth among the sector.
0.70%
Payables growth below half of Medical - Pharmaceuticals median of 3.30%. Joel Greenblatt sees more conservative payables management vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-67.86%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-85.03%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
254.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-1.10%
Below half Medical - Pharmaceuticals median of 0.39%. Joel Greenblatt sees more conservative short-term leverage than peers.
-9.10%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
100.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger extended contract coverage.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
81.66%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-4.34%
Above 1.5x Medical - Pharmaceuticals median of -1.16%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-1.31%
Above 1.5x Medical - Pharmaceuticals median of -0.82%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
2.81%
Below half Medical - Pharmaceuticals median of -0.85%. Jim Chanos suspects poor profitability or large dividend drains.
10.53%
AOCI growth below half of Medical - Pharmaceuticals median -0.48%. Joel Greenblatt sees fewer exposures vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.68%
≥ 1.5x Medical - Pharmaceuticals median of 1.36%. Joel Greenblatt sees stronger equity growth vs. peers.
0.68%
0.75-0.9x Medical - Pharmaceuticals median of 0.79%. John Neff wonders if expansions lag peers.
417660.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-50.19%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-1.05%
Below half of Medical - Pharmaceuticals median 1.28%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.